Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses

Phase

N/A

Condition

Digestive System Neoplasms

Treatment

N/A

Clinical Study ID

NCT04603586

Changhai Hospit

Ages 18-75
All Genders

Study Summary

The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (60-70Gy Vs.>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

18≤Age≤75 years
Cytologically or histologically verified pancreatic adenocarcinoma or clinicallydiagnosed as pancreatic cancer by multidisciplinary consultation
locally advanced pancreatic cancer (LAPC)
SBRT was not preceded by any targeted antitumor therapy
ECOG 0-1
Written informed consent according to ICH/GCP regulations before registration andprior to any trial specific procedures

Exclusion

Exclusion Criteria:

Patients who have previously received related treatment because of pancreaticadenocarcinoma, such as radiotherapy, chemotherapy or focal treatment
Patients with severe liver or kidney dysfunction
Patients with obstructive jaundice
Patients with mass ascites
Patients participated in other clinical trials for less than three months
Patients with other malignancies, or acute or other severe infections, with ulcerativecolitis, inflammatory bowel disease, ect
Unsuitable to participate in this clinical trial judged by the investigator

Study Design

October 20, 2020

October 01, 2023

Connect with a study center

Changhai hospital
Shanghai, Shanghai 200433
China
Active - Recruiting
Shanghai Changhai Hospital
Shanghai, Shanghai 200433
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.